Publication:

Randomized, Double-Blind, Placebo-Controlled Crossover Trial of Once Daily Empagliflozin 25 mg for the Treatment of Postprandial Hypoglycemia After Roux-en-Y Gastric Bypass

Date

Date

Date
2023
Journal Article
Published version

Citations

Citation copied

Ferreira, A., Schönenberger, K. A., Potoczna, N., Vogt, A., Gerber, P. A., Zehetner, J., Giachino, D., Nett, P., Gawinecka, J., Cossu, L., Fuster, D. G., Dalla Man, C., Facchinetti, A., Melmer, A., Nakas, C. T., Hepprich, M., Donath, M. Y., Herzig, D., & Bally, L. (2023). Randomized, Double-Blind, Placebo-Controlled Crossover Trial of Once Daily Empagliflozin 25 mg for the Treatment of Postprandial Hypoglycemia After Roux-en-Y Gastric Bypass. Diabetes Technology & Therapeutics, 25(7), 467–475. https://doi.org/10.1089/dia.2023.0036

Abstract

Abstract

Abstract

Aims: To investigate the effect of empagliflozin on glucose dynamics in individuals suffering from postbariatric hypoglycemia (PBH) after Roux-en-Y gastric bypass (RYGB).

Methods: Twenty-two adults with PBH after RYGB were randomized to empagliflozin 25 mg or placebo once daily over 20 days in a randomized, double-blind, placebo-controlled, crossover trial. The primary efficacy outcome was the amplitude of plasma glucose excursion (peak to nadir) during a mixed-meal tolerance test (MMTT). Outcomes of the outpatient period were assess

Additional indexing

Creators (Authors)

  • Ferreira, Antonio
    affiliation.icon.alt
  • Schönenberger, Katja A
    affiliation.icon.alt
  • Potoczna, Natascha
    affiliation.icon.alt
  • Vogt, Andreas
    affiliation.icon.alt
  • Gerber, Philipp A
    affiliation.icon.alt
  • Zehetner, Jörg
    affiliation.icon.alt
  • Giachino, Daniel
    affiliation.icon.alt
  • Nett, Philipp
    affiliation.icon.alt
  • Gawinecka, Joanna
    affiliation.icon.alt
  • Cossu, Luca
    affiliation.icon.alt
  • Fuster, Daniel G
    affiliation.icon.alt
  • Dalla Man, Chiara
    affiliation.icon.alt
  • Facchinetti, Andrea
    affiliation.icon.alt
  • Melmer, Andreas
    affiliation.icon.alt
  • Nakas, Christos T
    affiliation.icon.alt
  • Hepprich, Matthias
    affiliation.icon.alt
  • Donath, Marc Y
    affiliation.icon.alt
  • Herzig, David
    affiliation.icon.alt
  • Bally, Lia
    affiliation.icon.alt

Journal/Series Title

Journal/Series Title

Journal/Series Title

Volume

Volume

Volume
25

Number

Number

Number
7

Page range/Item number

Page range/Item number

Page range/Item number
467

Page end

Page end

Page end
475

Item Type

Item Type

Item Type
Journal Article

Dewey Decimal Classifikation

Dewey Decimal Classifikation

Dewey Decimal Classifikation

Keywords

Medical Laboratory Technology, Endocrinology, Endocrinology, Diabetes and Metabolism

Language

Language

Language
English

Publication date

Publication date

Publication date
2023-07-01

Date available

Date available

Date available
2023-09-05

Publisher

Publisher

Publisher

ISSN or e-ISSN

ISSN or e-ISSN

ISSN or e-ISSN
1520-9156

Additional Information

Additional Information

Additional Information
Final publication is available from Mary Ann Liebert, Inc., publishers http://dx.doi.org/10.1089/dia.2023.0036

OA Status

OA Status

OA Status
Green

PubMed ID

PubMed ID

PubMed ID

Citations

Citation copied

Ferreira, A., Schönenberger, K. A., Potoczna, N., Vogt, A., Gerber, P. A., Zehetner, J., Giachino, D., Nett, P., Gawinecka, J., Cossu, L., Fuster, D. G., Dalla Man, C., Facchinetti, A., Melmer, A., Nakas, C. T., Hepprich, M., Donath, M. Y., Herzig, D., & Bally, L. (2023). Randomized, Double-Blind, Placebo-Controlled Crossover Trial of Once Daily Empagliflozin 25 mg for the Treatment of Postprandial Hypoglycemia After Roux-en-Y Gastric Bypass. Diabetes Technology & Therapeutics, 25(7), 467–475. https://doi.org/10.1089/dia.2023.0036

Green Open Access
Loading...
Thumbnail Image

Files

Files

Files
Files available to download:1

Files

Files

Files
Files available to download:1
Loading...
Thumbnail Image